SLC5A2 and heart failure: In this cohort study of 28 075 patients with heart failure naive to sodium-glucose cotransporter-2 inhibitor therapy, patients who started using empagliflozin were less likely to experience the primary outcome of composite of all-cause mortality or hospitalization compared with those who started using dapagliflozin.